bims-proned Biomed News
on Proteostasis in neurodegeneration
Issue of 2026–04–12
thirteen papers selected by
Verena Kohler, Umeå University



  1. Commun Chem. 2026 Apr 08.
      Amyloid deposition is a hallmark of numerous age-related diseases, and understanding the chemical mechanisms that govern amyloid formation is crucial for advancing the rational development of protein aggregation inhibitors. With amyloid formation rates varying widely across proteins, here we report the quantitative aggregation mechanism of medin, the most common localized amyloid in humans, and find it to be much faster compared to well-known pathological amyloids such as amyloid-β (Aβ), tau and α-synuclein. We report the microscopic rate constants and reaction orders of medin fibril formation by monitoring the aggregation of recombinant human medin in vitro via a fluorescence-based assay, global kinetic modeling, secondary structure analysis and electron microscopy. Medin spontaneously forms amyloid fibrils at physiological pH and temperature in quiescent solution at concentrations as low as 25 nM, with the highest fibril elongation rate constant when compared to those of Aβ, tau and α-synuclein. Our results identify the microscopic basis of the widespread observation of medin aggregates upon aging, offering a mechanistic starting point for drug discovery to inhibit medin aggregation.
    DOI:  https://doi.org/10.1038/s42004-026-01950-7
  2. ChemMedChem. 2026 Apr 14. 21(7): e202500890
      Parkinson's disease (PD) is a prevalent age-related neurodegenerative syndrome, partially thought to be caused by a decrease in α-synuclein proteostasis. Anle138b = 5-(1,3-benzodioxol-5-yl)-3-(3-bromophenyl)-1H-pyrazole (HL) is undergoing clinical trials as a promising mitigator of α-synuclein aggregation. Because complexation to metals is known to modulate the activity of several drugs, we have prepared and characterized: H2L(ClO4), [CuI(µ-L)]3, and [AgI(µ-L)]3. To better understand the bioviability of these compounds, we monitored their effects in a cell culture model of α-synuclein protein aggregation using human α-synuclein preformed fibrils (PFFs). Using two different anti-α-synuclein antibodies, our data suggest that [AgI(µ-L)]3 decreases a C-terminal truncated protein that is approximately 12.4 kDa, as well as increases the size and alters the shape of PFF-induced aggregates. This indicates that [AgI(µ-L)]3 impacts aggregation in a manner different from HL and may serve as a novel tool for studying C-terminal truncation-related aggregation chemistry.
    Keywords:  Edman sequencing; Parkinson's disease; X‐ray crystallography; confocal microscopy; α‐synuclein
    DOI:  https://doi.org/10.1002/cmdc.202500890
  3. J R Soc Interface. 2026 Apr 08. pii: 20251037. [Epub ahead of print]23(237):
      Protein aggregation underlies the pathogenesis of many neurodegenerative diseases, and inhibitors are often assumed to elicit monotonic dose-responses. We ask whether simple aggregation pathways can intrinsically generate hormesis-a biphasic profile with low-dose stimulation and high-dose inhibition. We formulate a minimal mechanistic model in which a single inhibitor interacts sequentially with pathway intermediates. Analysis and simulation show a robust non-monotonic response: low inhibitor doses increase aggregate formation, whereas high doses suppress it. We prove that this profile is structural-arising from chemical network topology rather than tuned kinetic parameters. The mechanism rationalizes pro-aggregating effects at low doses and underscores the need for full-range dose-response evaluation in inhibitor screening.
    Keywords:  biphasic dose–response; hormesis; inhibitor screening; mathematical modelling; ordinary differential equations; protein aggregation; reaction network topology
    DOI:  https://doi.org/10.1098/rsif.2025.1037
  4. J Cell Mol Med. 2026 Apr;30(7): e71132
      Parkinson's disease (PD) is characterised by progressive neurodegeneration and is marked by the formation of Lewy bodies, which are intracellular aggregates primarily composed of α-synuclein. Mitochondrial dysfunction and impaired protein degradation pathways are thought to play critical roles in PD progression, contributing to the loss of dopaminergic neurons in the substantia nigra. Phosphorylation of α-synuclein has been shown to promote its aggregation, underscoring its potential role in disease progression. Parkin, an E3 ubiquitin ligase, is widely regarded as a pleiotropic neuroprotective protein that modulates the mitochondrial quality control, as well as metabolic turnover and the accumulation of α-synuclein. Death-associated protein kinase 1 (DAPK1), which is involved in the regulation of apoptosis and autophagy, has recently emerged as an important factor in neurodegeneration. While DAPK1 has been implicated in Alzheimer's disease through its role in tau aggregation and amyloid-β production, our findings suggest that DAPK1 may also influence PD-related pathways by phosphorylating parkin at Ser136 and Ser198. This phosphorylation promotes the mitochondrial transport of parkin, enhancing interaction with mitochondria-localised E3 ubiquitin ligase MITOL and consequently leading to the degradation of parkin. Given the neuroprotective role of parkin, its reduction increases the vulnerability of neurons to 6-hydroxydopamine-induced toxicity, potentially contributing to decreased neuronal survival. Together, these findings suggest that DAPK1 functions as a previously unrecognised modulator of parkin and could potentially influence PD-related neurodegenerative processes. This pathway may provide a mechanistic link between mitochondrial dysfunction, α-synuclein pathology and neuronal cell death.
    Keywords:  6‐OHDA; DAPK1; MITOL; neuronal toxicity; parkin; phosphorylation; ubiquitination
    DOI:  https://doi.org/10.1111/jcmm.71132
  5. bioRxiv. 2026 Mar 30. pii: 2026.03.27.714902. [Epub ahead of print]
      Loss of proteostasis and the accumulation of insoluble protein aggregates are features of aging across model organisms and occur in all major age-related neurodegenerative diseases; yet how aggregation proceeds during normal human brain aging remains unknown. Here, using detergent-fractionation proteomics, we show that brain aging does not involve uniform aggregate accumulation; rather, the insoluble proteome undergoes asymmetric remodeling beginning in midlife, with maximum-stability aggregates declining sharply by old age and intermediate-stability aggregates accumulating progressively before accelerating after age 80. Intermediate-stability aggregates are prone to liquid-liquid phase separation and are enriched among Alzheimer's disease plaque and tangle constituents. Proteasome and cytosolic chaperone capacity predict individual differences in aggregate burden as strongly as chronological age, offering human-level evidence in support of therapies targeting these pathways. These findings establish aggregate remodeling as a feature of normal brain aging and position intermediate-stability aggregate accumulation as a molecular event on the path to neurodegenerative disease.
    DOI:  https://doi.org/10.64898/2026.03.27.714902
  6. bioRxiv. 2026 Mar 30. pii: 2026.03.26.714051. [Epub ahead of print]
       Background: α-Synuclein (α-Syn) plays a central role in Parkinson's disease (PD). Under pathological conditions, α-Syn aggregates into toxic oligomers and fibrils that act as damage-associated molecular patterns (DAMPs), stimulating microglial reactivity. This α-Syn-microglia axis creates a self-perpetuating cycle of neuroinflammation and neurodegeneration, accelerating dopaminergic neuron loss in the substantia nigra pars compacta (SNpc) and contributing to motor deficits. Moreover, α-Syn pathology spreads through the brain, disrupting synaptic plasticity in cognitive regions like the cortex and hippocampus, leading to early cognitive decline. Thus, targeting α-Syn aggregation and its inflammatory consequences presents a promising dual-hit therapeutic strategy for PD.
    Methods: This study investigates the therapeutic potential of 3-monothiopomalidomide (3MP), a novel thalidomide derivative designed to reduce neuroinflammation with a potentially better safety profile than Pomalidomide (POM). The neuroprotective and anti-inflammatory effects of 3MP were evaluated in rat primary mesencephalic mixed neuron-microglia cultures exposed to human α-Syn oligomers (H-αSynOs). Anti-aggregation activity was assessed via Thioflavin T (ThT) assays and Thioflavin S (ThS) staining in SH-SY5Y cells. Finally, the anti-aggregation, anti-inflammatory, and neuroprotective effects of 3MP were evaluated in vivo in a rat model of PD induced by intracerebral infusion of H-αSynOs.
    Results: In primary cell cultures, 3MP dose-dependently reduced α-Syn-induced neuronal death and microglial inflammatory responses. It also significantly inhibited α-Syn aggregation in vitro in the ThT assay and in SH-SY5Y cells exposed to α-Syn protofibrils, outperforming POM. When chronically administered in vivo , 3MP preserved dopaminergic neurons within the SNpc and yielded functional benefits on motor and cognitive readouts. Notably, 3MP markedly attenuated α-Syn aggregates induced by the H-αSynOs infusion in the SNpc more efficiently than POM, as shown by reduced intraneuronal staining for pSer129-α-Syn+ and reduced pSer129-αSyn in both cytoplasmic and phagolysosomal compartments of microglia. In addition, mesencephalic and cortical inflammatory microgliosis that followed to intranigral H-αSynOs-infusion, were significantly dampened by 3MP.
    Conclusions: Overall, 3MP emerges as a dual-action drug candidate capable of modulating neuroinflammation and α-Syn aggregation and thereby disrupting the α-Syn-driven inflammatory cycle. Its neuroprotective effects and favourable safety profile support its potential as a disease-modifying therapy for PD, with promising implications for clinical translation.
    DOI:  https://doi.org/10.64898/2026.03.26.714051
  7. Alzheimers Dement. 2026 Apr;22(4): e71352
       INTRODUCTION: Proteostasis dysfunction is a hallmark of frontotemporal dementia (FTD) and Alzheimer's disease (AD), yet the genetic and molecular pathways that disrupt protein homeostasis remain poorly understood.
    METHODS: We integrated human genetics, transcriptomics, and functional studies to identify proteostasis network components involved in tauopathy.
    RESULTS: We identified 18 proteostasis network genes harboring 75 rare, damaging variants enriched in FTD and/or AD. These genes, spanning multiple proteostasis pathways, were differentially expressed in microtubule associated protein tau (MAPT) mutant neurons and dysregulated in FTD and AD brains. NINL, which encodes Nlp, emerged as the only gene consistently upregulated across all datasets. NINL overexpression reduced tau seeding and enhanced lysosomal proteolytic activity, whereas two FTD-enriched NINL frame shift variants impaired Nlp expression and abolished these protective effects.
    DISCUSSION: We identified a set of proteostasis genes with genetic and transcriptional links to neurodegeneration and revealed NINL as a novel regulator of tau aggregation.
    Keywords:  Alzheimer's disease; NINL; autophagy lysosomal pathway; brain tissue; frontotemporal dementia; functional genomics; human genetics; proteostasis; stem cell models; tau; tau aggregation; tauopathy
    DOI:  https://doi.org/10.1002/alz.71352
  8. J Am Chem Soc. 2026 Apr 08.
      Fibrillar aggregates of the natively disordered protein α-synuclein (αS) are hallmarks of Parkinson's disease and related neurodegenerative disorders termed synucleinopathies. Here, we used micromap (μMap) photoproximity labeling to determine the interactomes of αS monomers and fibrils in mouse brain lysate to better understand both the loss of healthy function and gain of toxic function aspects of synucleinopathies. Several αS variants were synthesized and characterized, showing that the small size (1 kDa) of the Ir catalyst attached through a Cys-maleimide linkage makes it minimally perturbing to αS, with a narrow labeling radius that allows one to identify interactome differences between different regions of αS. Monomer and fibril interactomes were compared to each other and to previous proximity labeling data sets for validation, and several examples of further investigations are demonstrated, including Western blotting, affinity pulldowns, fluorescence and super-resolution microscopy, and μMap in primary neurons.
    DOI:  https://doi.org/10.1021/jacs.5c16598
  9. Sci Rep. 2026 Apr 04.
      SOD1 misfolding leads to protein aggregation, which is a common feature of neurodegenerative diseases such as ALS. The effect of epigallocatechin gallate (EGCG) as a potent anti-amyloidogenic polyphenol on the G138E-SOD1 mutant was investigated using computational/experimental approaches. MD simulation results (RMSD, RMSF, Rg, SASA, PCA, and FEL) showed that EGCG binding stabilizes the mutant in a structure closer to the native structure, which was consistent with the FTIR and DSSP results. Intrinsic fluorescence spectroscopy calculated Ksv and Kq values as 1.8 × 104 M-1 and 5.8 × 1012 M-1s-1, respectively, indicating the participation of a static quenching mechanism. TEM images provide compelling evidence for the potential inhibitory effect of EGCG on protein aggregates in the G138E mutant, confirming the results of the ThT assay. DLS results showed a reduction in the size of aggregated particles in the presence of 80 μM EGCG, confirming the inhibition of amyloid aggregation by this compound. Finally, MTT assay on SH-SY5Y cells showed that cell survival in the presence of SOD1-G138E aggregates was approximately 40%, which increased to 60% with the addition of 80 μM EGCG. Taken together, this study suggests that EGCG may inhibit amyloid aggregation and reduce cytotoxicity by affecting nucleation and structural stabilization, making it a promising compound for ALS therapeutic strategies.
    Keywords:  ALS; EGCG; Protein aggregation; SH-SY5Y cells; SOD1
    DOI:  https://doi.org/10.1038/s41598-026-42742-2
  10. bioRxiv. 2026 Mar 13. pii: 2026.03.12.711310. [Epub ahead of print]
      Mitochondrial dysfunction and extracellular protein aggregation occur in neurodegenerative diseases such as Alzheimer's disease (AD). However, it remains unclear if these processes are functionally linked. Here, we identify a signaling pathway that is activated upon accumulation of aggregation-prone proteins in the extracellular space. We find that the transcription factor ATFS-1, which regulates the mitochondrial unfolded protein response, also regulates transcripts required for endosomal recycling, multiple plasma membrane-localized signaling receptors, and secreted proteins that bind aggregation-prone proteins in the extracellular space, including transthyretin and Aβ, and promote their degradation. Interestingly, Aβ(1-42) aggregation induces atfs-1 -dependent transcription by promoting degradation of the bZIP protein ZIP-3, which antagonizes ATFS-1. ZIP-3 accumulates in the cytosol when it is phosphorylated by kinases that function downstream of plasma membrane-localized signaling receptors, including the WNT and glutamate receptors. Upon ligand binding, the signaling receptors stimulate the cognate kinase, many of which we found phosphorylate ZIP-3, impeding ZIP-3 degradation, allowing it to antagonize atfs-1 -dependent transcription. However, accumulation of aggregation-prone proteins such as Aβ(1-42) causes endosomal swelling, which impairs endosomal recycling, instead diverting signaling receptors to lysosomes for degradation. In turn, the depletion of signaling receptors reduces the level of ZIP-3 phosphorylation, resulting in ZIP-3 degradation and activation of atfs-1 -dependent transcription, which promotes extracellular proteostasis. Our findings uncover an unexpected coupling between endocytic quality control and mitochondrial signaling, revealing a circuit that preserves extracellular proteostasis and promotes organismal resilience.
    DOI:  https://doi.org/10.64898/2026.03.12.711310
  11. bioRxiv. 2026 Apr 01. pii: 2026.03.30.715195. [Epub ahead of print]
       Background: Filamentation induced by cAMP domain-containing protein (FICD) is an endoplasmic reticulum (ER)-resident adenylyltransferase that catalyzes protein AMPylation, a post-translational modification. Although FICD-mediated AMPylation has been linked to the fine-tuning of proteostasis and neuronal integrity, its role in neurodegenerative diseases characterized by protein dyshomeostasis remains unclear. Parkinson's disease (PD) is defined by dopaminergic neurodegeneration and aggregation of α-synuclein (aSyn) as a consequence of impaired protein homeostasis. We therefore investigated whether dysregulated FICD-mediated AMPylation contributes to PD pathogenesis.
    Methods: We combined analyses of human post-mortem PD brain tissue with complementary models, including midbrain dopaminergic neurons derived from human induced pluripotent stem cells (hiPSCs) of a PD patient carrying an SNCA gene duplication and its isogenic gene dosage-corrected control line, transgenic mouse models of synucleinopathy, and an aSyn-overexpressing H4 neuroglioma cell model. Genetic and pharmacological modulation of FICD activity was integrated with multi-proteomic approaches, including chemical proteomics-based AMPylation profiling, stable isotope labelling with amino acids in cell culture-based global protein turnover analysis, and whole-proteome profiling to identify AMPylation-associated molecular pathways.
    Results: FICD was preferentially expressed in dopaminergic neurons and was upregulated in SNCA duplication PD patient-derived neurons, as well as in the basal ganglia of PD post-mortem brains and synucleinopathy mice. Despite this overall increase, the proportion of FICD-expressing dopaminergic neurons was reduced under PD conditions, suggesting selective vulnerability of dopaminergic neurons to FICD. Mechanistically, FICD selectively AMPylated lysosomal proteins, thereby linking AMPylation to the regulation of degradative pathways. Moreover, hyperactivation of FICD-induced AMPylation triggered ER stress, impaired lysosomal function, reduced protein turnover, and ultimately promoted aSyn aggregation and apoptotic cell death. Importantly, pharmacological inhibition of AMPylation reversed aSyn pathology and neurite degeneration in PD patient-derived neurons.
    Conclusions: We identify the pathological relevance of FICD-mediated AMPylation in PD-related neurodegeneration and its contribution to aSyn aggregation through a bidirectional interplay with aSyn pathology. Our findings support FICD-mediated AMPylation as a defining molecular switch regulating intracellular protein homeostasis in PD and highlight the FICD-AMPylation pathway as a potential therapeutic target for restoring aSyn pathology and mitigating disease progression.
    DOI:  https://doi.org/10.64898/2026.03.30.715195
  12. Int J Biol Macromol. 2026 Apr 03. pii: S0141-8130(26)01737-X. [Epub ahead of print]359 151811
      Proteostasis is fundamental to cellular health, and its decline is a hallmark of aging. The ubiquitin-proteasome system (UPS) constitutes a critical regulatory node within the proteostasis network, and its function is largely dictated by the dynamic interplay between E3 ubiquitin ligases and deubiquitinating enzymes (DUBs). The nematode Caenorhabditis elegans (C. elegans) serves as a powerful model for dissecting this relationship in the context of aging, because of its genetic tractability and conserved proteostatic machinery. However, while studies in C. elegans have yielded fundamental insights, translational extrapolation requires caution. The worm lacks endogenous counterparts to key human amyloidogenic proteins, such as α-synuclein and 42-amino acid amyloid-beta (Aβ), and the functional scope of conserved UPS components, such as the Parkin homolog PDR-1, is often narrower than in humans, lacking the complexity of cross-pathway crosstalk. This article explores how UPS regulates proteostasis to promote healthy aging in C. elegans, synthesizing recent advances in its molecular mechanisms and potential interventions. This review provides the first systematic integration of existing findings to decipher how UPS components, specifically E3 ubiquitin ligases and proteasomes, regulate protein degradation in C. elegans and impact lifespan. Additionally, the ways in which natural and chemical compounds can potentially enhance UPS function to improve organismal health and delay aging were investigated. By reviewing the impact of the broader proteostasis network on aging and highlighting the regulatory role of UPS, while contextualizing the strengths and limitations of the C. elegans model, this review provides insights into potential anti-aging strategies and therapeutic approaches for age-related diseases.
    Keywords:  Healthy aging; Protein homeostasis; Ubiquitin-proteasome system
    DOI:  https://doi.org/10.1016/j.ijbiomac.2026.151811
  13. ACS Omega. 2026 Mar 31. 11(12): 19124-19133
      TAR DNA-binding protein (TDP-43) has been identified as a major pathological protein in several neurodegenerative diseases. The stable, folded structure of its N-terminal domain (NTD) is thought to be requisite for its physiological function, with any structural disruption potentially leading to aberrant aggregation. In the present study, we have employed long, unbiased all-atom molecular dynamics (MD) simulations to study the conformational stability of the NTD monomer and two of its mutants (L27A and L28A). Since the choice of force field can significantly impact simulation outcomes, we used two different force fields (CHARMM36m and CHARMM36mW). In agreement with experimental data, our simulations using both force fields conclusively demonstrate that the wild-type NTD and the L27A mutant remain structurally stable, while the L28A mutation significantly disrupts tertiary contacts, exposing buried hydrophobic residues and thereby destabilizing the folded structure. Furthermore, across all systems, CHARMM36m simulations exhibited greater overall stability than CHARMM36mW, consistent with our previous study on Aβ fibrils. Importantly, our simulations provide mechanistic insights at the atomic level with significant implications for understanding the NTD's role in both normal cellular function and pathological aggregation.
    DOI:  https://doi.org/10.1021/acsomega.5c11735